AGCO Agriculture Foundation Donates to UK's Biggest Charity Fighting Hunger and Tackling Food Waste
28.11.2022 22:52:00 EET | Business Wire | Press release
The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a USD 300,000 grant to FareShare to ensure surplus food reaches vulnerable communities in the United Kingdom while tackling food waste.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005695/en/
AAF grant to FareShare to secure 475 tonnes of surplus food. (Photo: Business Wire)
The two-year partnership is expected to help FareShare secure 475 tonnes of surplus food and redistribute more than one million meals. The project will assist in growing the award-winning Surplus with Purpose Fund, which covers the cost for farmers to harvest and divert food that would have otherwise been wasted.
The Intergovernmental Panel on Climate Change estimates that food waste contributes between 8 and 10 percent of global greenhouse gas emissions, so tackling food waste is a pressing issue. The funding will also directly help agricultural businesses by reducing the environmental effect of food waste through interventions to harvest fresh surplus products such as fruit and vegetables. Over the next 24 months, for every tonne of surplus food FareShare and AAF redistribute through this project, approximately 1.6 tonnes of embedded CO2 could be saved, and another 3.8 tonnes could be prevented from harmful alternative disposal.
"As a foundation, our support of the FareShare surplus food project comes at a crucial time and aligns with AAF's vision to prevent and relieve hunger. We hope to support the food needs of these vulnerable households while combating climate change at both ends of the food chain by tackling food waste," said Roger Batkin, Board Chair, AGCO Agriculture Foundation.
The AAF-funded surplus food project contributes to four of The United Nations' 17 Sustainable Development Goals: Zero Hunger, Good Health and Well-being, Climate Action and Responsible Consumption and Production. The project will supply food for thousands of vulnerable people, tackle food waste to address climate change impact, improve overall well-being through access to good nutrition and provide a scalable solution to rescue food.
"We should never be wasting good food, especially not amid a cost-of-living crisis. Millions of people are struggling with the rise in food prices, fuel and household bills. We've seen the impact of demand for food across our network skyrocketing. FareShare is grateful to the AAF for extending their funding to the UK at this crucial time. This partnership will help us further our reach and make a meaningful difference in getting surplus food from farms to people's plates," said Lindsay Boswell, Chief Executive Officer of FareShare.
About AGCO
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Challenger®, Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO's full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $11.1 billion in 2021. For more information, visit www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
About the AGCO Agriculture Foundation (AAF)
The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcofoundation.org/
About FareShare
FareShare is the UK's biggest charity fighting hunger and tackling food waste since 1994. The charity organization is born out of the belief that no good food should go to waste, especially when people are going hungry. FareShare redistributes its surplus food through a network of nearly 9,500 charities and community organizations.
For more information, visit our website: https://fareshare.org.uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005695/en/
Contact information
Aryn Drawdy, Corporate Communications Director
aryn.drawdy@agcocorp.com
Holly Howells, FareShare
Holly.Howells@fareshare.org.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom